Antibody Fc:
Linking Adaptive and Innate Immunity
Edited by- Margaret Ackerman, Dartmouth College, Hanover, NH, USA
This is the first comprehensive text to synthesize the literature, describing these functions and presenting the variety of human genetic, mouse model, in vitro and providing clinical evidence of the importance and the dramatic variability of antibodies to influence the immune response. Antibodies represent the correlate of protection for numerous vaccines, and are the most rapidly growing class of drugs, representing a tremendous economic and therapeutic sector ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells, as well as providing a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. Despite its nomenclature, a number of factors influence the ability of the constant domain to recruit effector mechanisms. There is a vast literature regarding antibody effector function, indicating that it is a high impact and dynamic area.
Audience
vaccinologists, immunologists, microbiologists, oncologists, protein engineers, in academic and industrial research institutions; graduate students in immunology and vaccinology.
Hardbound, 450 Pages
Published: October 2013
Imprint: Academic Press
ISBN: 978-0-12-394802-1
Contents
Part 1: Effector Mechanisms
Ch 1: ADCC: Antibody dependent cellular cytotoxicity
Ch 2:. ADCP: Antibody dependent cellular phagocytosis
Ch 3: ADCDC: Antibody dependent complement dependent cytotoxicity
Ch 4: Trapping in mucusPart 2: Effector Cells
Ch 5: NK cells
Ch 6: Phagocytes
Ch 7: B cellsPart 3: FcR
Part 4: Variability of the Fc Domain
Ch 8: Activating Receptors FcgR1, FcgR2a, FcgR3a
Ch 9: Inhibitory receptor FcgR2b
Ch 10: Comparison of human, mouse, and primate FcgR
Ch 11: Antibody Subclasses
Ch 12: Antibody GlycosylationPart 5: Genetic Associations
Part 6: Evolving areas
Ch 13: Autoimmunity
Ch 14: Infectious disease
Ch 15: Monoclonal Antibody Therapy
Ch 16: Competition between mechanisms
Ch 17: Fc driven immunotherapy
Ch 18: FcR as therapeutic targets
Ch 19: Engineered Fc domains
Ch 20: Tolerizing vs activating pathways
Ch 21: Defense/evasion mechanisms against Fc activity
Ch 22: Pathogenic exploitation of Fc activity

